• News
  • North America

VitriVax Closes $87 Million Series C Financing

Funding will advance a Lyme disease vaccine candidate into first-in-human testing.

11/18/2026
•Ghita Khalfaoui
Back to News

VitriVax closed an oversubscribed $87 million Series C financing. F-Prime, NEA, RA Capital Management, and Sanofi Ventures co-led the round. Eli Lilly and other existing investors also participated.


Use of proceeds

The new capital will help move its Lyme disease vaccine candidate into first-in-human testing. It will also support pipeline expansion based on the ALTA platform. The round follows a $17.25 million Series B completed in September 2025.

Company context

VitriVax is headquartered in Boulder, Colorado. It develops vaccine candidates and formulation technology. Its lead program targets Lyme disease, the most common vector-borne disease in the United States and Europe.

What the platform does

ALTA is designed to enable single-dose administration and balanced immune responses. It can also spare antigens and adjuvants while lowering cost of goods. The system has been extended to deliver mRNA without lipid nanoparticles.


VitriVax plans to generate first-in-human data for its Lyme candidate. It will also build a portfolio of proprietary programs. The company will continue working with global health partners to expand vaccine access.